Mosunetuzumab, CAS 1905409-39-3

Product Description: Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs)[1][2].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Gregory Z Ferl, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018 May;11(3):296-304. /[2]Lihua E Budde, et al. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022 Feb 10;40(5):481-491.

CAS Number: 1905409-39-3

Molecular Weight: N/A

Compound Purity: 99.05

Research Area: Cancer; Inflammation/Immunology

Solubility: H2O

Target: CD20;CD3

• Artikelnummer: MEXHY-P99033-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99033-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK